Last reviewed · How we verify
EKB-569
EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Used for Non-small cell lung cancer.
At a glance
| Generic name | EKB-569 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
EKB-569 works by selectively binding to the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting the enzyme's activity and blocking the downstream signaling pathways that promote cell proliferation and survival.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Rash
- Fatigue
Key clinical trials
- CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors (PHASE1)
- Study Evaluating EKB-569 in Advanced Colorectal Cancer (PHASE2)
- Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EKB-569 CI brief — competitive landscape report
- EKB-569 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI